69 related articles for article (PubMed ID: 27713162)
1. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma.
Zhuang H; Bai J; Chang JY; Yuan Z; Wang P
Oncotarget; 2016 Dec; 7(51):84688-84694. PubMed ID: 27713162
[TBL] [Abstract][Full Text] [Related]
2. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
Rachamala HK; Madamsetty VS; Angom RS; Nakka NM; Dutta SK; Wang E; Mukhopadhyay D; Pal K
J Exp Clin Cancer Res; 2024 Jun; 43(1):159. PubMed ID: 38840237
[TBL] [Abstract][Full Text] [Related]
3. Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.
Mantovani FB; Morrison JA; Mutsaers AJ
BMC Vet Res; 2016 May; 12():82. PubMed ID: 27245053
[TBL] [Abstract][Full Text] [Related]
4. PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
Xu X; Liu Y; Gong Q; Ma L; Wei W; Zhao L; Luo Z
Cancer Chemother Pharmacol; 2024 Apr; ():. PubMed ID: 38609654
[TBL] [Abstract][Full Text] [Related]
5. Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma.
Codina-Martínez H; Lorenzo-Guerra SL; Cabal VN; García-Marín R; Suárez-Fernández L; Vivanco B; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894790
[TBL] [Abstract][Full Text] [Related]
6. mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice.
Wu W; Jin Q; Östlund C; Tanji K; Shin JY; Han J; Leu CS; Kushner J; Worman HJ
Circ Heart Fail; 2024 Apr; 17(4):e011110. PubMed ID: 38567527
[TBL] [Abstract][Full Text] [Related]
7. Targeting ROR1 inhibits epithelial to mesenchymal transition in human lung adenocarcinoma via mTOR signaling pathway.
Long MP; Wang HL; Luo YB; Yang JH
Int J Clin Exp Pathol; 2018; 11(10):4759-4770. PubMed ID: 31949551
[TBL] [Abstract][Full Text] [Related]
8. Effects of Everolimus in Modulating the Host Immune Responses against
Raien A; Davis S; Zhang M; Zitser D; Lin M; Pitcher G; Bhalodia K; Subbian S; Venketaraman V
Cells; 2023 Nov; 12(22):. PubMed ID: 37998388
[TBL] [Abstract][Full Text] [Related]
9. The radiation- and chemo-sensitizing capacity of diclofenac can be predicted by a decreased lactate metabolism and stress response.
Schwab M; Dezfouli AB; Khosravi M; Alkotub B; Bauer L; Birgani MJT; Multhoff G
Radiat Oncol; 2024 Jan; 19(1):7. PubMed ID: 38229111
[TBL] [Abstract][Full Text] [Related]
10. The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo.
Gonnissen A; Isebaert S; McKee CM; Dok R; Haustermans K; Muschel RJ
Oncotarget; 2016 Dec; 7(51):84286-84298. PubMed ID: 27713179
[TBL] [Abstract][Full Text] [Related]
11. WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.
Inamura K; Yokouchi Y; Kobayashi M; Sakakibara R; Ninomiya H; Subat S; Nagano H; Nomura K; Okumura S; Shibutani T; Ishikawa Y
Lung Cancer; 2016 Dec; 243():21-28. PubMed ID: 27721121
[TBL] [Abstract][Full Text] [Related]
12. The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.
Min YH; Kim W; Kim JE
Oncotarget; 2016 Dec; 7(51):84718-84735. PubMed ID: 27713168
[TBL] [Abstract][Full Text] [Related]
13. The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition.
Wu SG; Chang YL; Yu CJ; Yang PC; Shih JY
Sci Rep; 2016 Oct; 6():35249. PubMed ID: 27734950
[TBL] [Abstract][Full Text] [Related]
14. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
[TBL] [Abstract][Full Text] [Related]
15. Dichloroacetic acid and rapamycin synergistically inhibit tumor progression.
Chen H; Liang K; Hou C; Piao HL
J Zhejiang Univ Sci B; 2023 May; 24(5):397-405. PubMed ID: 37190889
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic activities are increased via upregulation of HIF-1α expression in gefitinib-resistant non-small cell lung carcinoma cells.
Cha JE; Bae WY; Choi JS; Lee SH; Jeong JW
Oncol Lett; 2021 Sep; 22(3):671. PubMed ID: 34345296
[TBL] [Abstract][Full Text] [Related]
17. Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting.
Hintelmann K; Kriegs M; Rothkamm K; Rieckmann T
Front Oncol; 2020; 10():1260. PubMed ID: 32903756
[TBL] [Abstract][Full Text] [Related]
18. Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments.
Kwon Y; Kim M; Jung HS; Kim Y; Jeoung D
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31527477
[TBL] [Abstract][Full Text] [Related]
19. ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.
Qi M; Tian Y; Li W; Li D; Zhao T; Yang Y; Li Q; Chen S; Yang Y; Zhang Z; Tang L; Liu Z; Su B; Li F; Feng Y; Fei K; Zhang P; Zhang F; Zhang L
Oncotarget; 2018 Feb; 9(15):12020-12034. PubMed ID: 29552290
[TBL] [Abstract][Full Text] [Related]
20. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.
Abrams SL; Ruvolo PP; Ruvolo VR; Ligresti G; Martelli AM; Cocco L; Ratti S; Tafuri A; Steelman LS; Candido S; Libra M; McCubrey JA
Oncotarget; 2017 Sep; 8(44):76525-76557. PubMed ID: 29100331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
